We are live on ! Find out more
TCRX icon

TScan Therapeutics
TCRX

73 hedge funds and large institutions have $62.9M invested in TScan Therapeutics in 2025 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 18 increasing their positions, 31 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

21% more capital invested

Capital invested by funds: $51.8M → $62.9M (+$11.1M)

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

2.35% less ownership

Funds ownership: 68.29% → 65.94% (-2.3%)

10% less funds holding

Funds holding: 81 → 73 (-8)

42% less repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 31

58% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 12

Holders
73
Holders Change
-8
Holders Change %
-9.88%
% of All Funds
0.96%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
5
Increased
18
Reduced
31
Closed
12
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Aberdeen Group
Aberdeen Group
United Kingdom
+$821K
2
Citadel Advisors
Citadel Advisors
Florida
+$304K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$299K
4
Two Sigma Advisers
Two Sigma Advisers
New York
+$132K
5
Two Sigma Investments
Two Sigma Investments
New York
+$96.3K

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$690K
2
Goldman Sachs
Goldman Sachs
New York
-$530K
3
BlackRock
BlackRock
New York
-$325K
4
Millennium Management
Millennium Management
New York
-$291K
5
PBM
Propel Bio Management
California
-$274K
Name Holding Trade Value Shares
Change 		Change in
Stake
Mariner
51
Mariner
Kansas
$29.2K -$1.81K -1,023 -6%
PAS
52
Point72 Asia (Singapore)
Singapore
$26.5K -$25.7K -14,535 -50%
Osaic Holdings
53
Osaic Holdings
Arizona
$21.9K – – –
Prudential Financial
54
Prudential Financial
New Jersey
$20.9K +$20.4K +11,500 New
TRCT
55
Tower Research Capital (TRC)
New York
$20.2K -$2.58K -1,456 -12%
UBS Group
56
UBS Group
Switzerland
$20.2K -$690K -389,328 -97%
AWM
57
Aries Wealth Management
Maine
$18.2K – – –
WPW
58
Waldron Private Wealth
Pennsylvania
$18.2K – – –
Fidelity Investments
59
Fidelity Investments
Massachusetts
$18.2K -$1.57K -885 -8%
CUAMC
60
China Universal Asset Management Company
China
$16.7K -$2.32K -1,310 -12%
Federated Hermes
61
Federated Hermes
Pennsylvania
$3.97K – – –
Mirae Asset Global Investments
62
Mirae Asset Global Investments
South Korea
$3.69K +$14 +8 +0.4%
Citigroup
63
Citigroup
New York
$1.98K -$18.9K -10,684 -91%
GFM
64
GF Fund Management
China
$1.86K -$351 -198 -16%
Nisa Investment Advisors
65
Nisa Investment Advisors
Missouri
$1.08K -$250 -141 -19%
Royal Bank of Canada
66
Royal Bank of Canada
Ontario, Canada
$1K +$1.3K +737 +1,068%
RWM
67
Rialto Wealth Management
New York
$694 – – –
SWP
68
Strategic Wealth Partners
Ohio
$566 – – –
SS
69
SBI Securities
Japan
$386 +$2 +1 +0.5%
Rockefeller Capital Management
70
Rockefeller Capital Management
New York
$364 +$354 +200 New
EWA
71
EverSource Wealth Advisors
Alabama
$118 -$9 -5 -7%
TWD
72
True Wealth Design
Ohio
$17 -$58 -33 -79%
TCA
73
Troluce Capital Advisors
Puerto Rico
– -$218K -150,000 Closed
YIH
74
Y-Intercept (HK)
Hong Kong
– -$111K -76,660 Closed
HF
75
HRT Financial
New York
– -$80K -55,369 Closed
1 2
3
4

TCRX Hedge Fund Activity: Q3 2025 in Review

73 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in TScan Therapeutics (TCRX) for Q3 2025, worth a combined $62.9M — up 21% from $51.8M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of TCRX and 5 opened new positions — a net loss of 7 holders — while 31 trimmed existing stakes and 18 added.

The largest buyer was Aberdeen Group, adding an estimated $821K. The largest seller was UBS Group, cutting an estimated $690K.

  • 73 institutional investors held TScan Therapeutics (TCRX) as of Q3 2025, down from 81 in Q2 2025.
  • Funds reported $62.9M of TScan Therapeutics stock for Q3 2025, up 21% quarter-over-quarter.
  • 5 funds opened new TScan Therapeutics positions in Q3 2025 and 12 closed out, a net change of -7 holders.
  • The largest TScan Therapeutics buyer in Q3 2025 was Aberdeen Group, an estimated $821K added.
  • The largest TScan Therapeutics seller in Q3 2025 was UBS Group, an estimated $690K sold.

Based on aggregated 13F filings for Q3 2025.